Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05768139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 17, 2023
Completion date
July 31, 2030
Enrollment
880 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, solid tumors, adult